Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Use of daratumumab in high risk multiple myeloma: A meta‐analysis

eJHaem(2020)10.1002/jha2.47Source: DataRank Database

Use of daratumumab in high risk multiple myeloma: A meta‐analysis is a research paper published in eJHaem (2020). On theSindex it has a DataRank of 0. It has been cited 26 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access26 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.17)OA: goldTopics (21)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Samuel Pan ORCID,Suzanne Lentzsch ORCID,Divaya Bhutani ORCID,Vikram Premkumar ORCID

Live enrichment

PubMed:35847747 PMC:PMC9175911 OpenAlex:https://openalex.org/W3040500450

Foundation for the National Institutes of Health

Grant: T32CA203703

National Institutes of Health

Grant: 5T32CA203703-02

Molecular Oncology Training Program

FWCI

2.17

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jha2.47

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jha2.47

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjha2.47

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.47

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/jha2.47

Fields of Study

Multiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsPeptidase Inhibition and Analysis03 medical and health sciences0302 clinical medicine

Keywords

DaratumumabInternal medicineMedicineRefractory (planetary science)OncologyMultiple myelomaRelative riskSurgeryConfidence intervalLenalidomideBiologyCytogeneticsImmunotherapyShort ReportsDiseases of the blood and blood-forming organsRC633-647.5

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being